TuesdayMar 18, 2025 12:51 pm

BioMedNewsBreaks — Why Soligenix Inc. (NASDAQ: SNGX) Is ‘One to Watch’

Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases with high unmet medical needs. “Operating through two key segments, the company’s Specialized BioTherapeutics division is dedicated to oncology and inflammation therapies, while its Public Health Solutions segment advances vaccines and therapeutics targeting biothreats and infectious diseases,” reads a recent article. “With a diversified pipeline, multiple orphan and fast-track designations, and collaborations with government agencies, Soligenix is uniquely positioned for potential regulatory approvals and commercialization.” To view the full article, visit https://ibn.fm/AUjKv About Soligenix Inc. Soligenix is a late-stage biopharmaceutical company focused on developing…

Continue Reading

FridayMar 14, 2025 3:45 pm

BioMedNewsBreaks — Adageis’ AI-Driven Approach: A Game-Changer in Efficient, Patient-Centered Healthcare

Adageis was featured in a recent article that discussed how its ProActive Care approach shifts healthcare from reactive to preventive, patient-centered care by leveraging AI-driven analytics to identify high-risk patients and address care gaps. This model enhances patient outcomes by focusing on early intervention, care coordination, more time with doctors to focus on patient needs, and better overall health management. For healthcare providers, it boosts operational efficiency and revenue potential through optimizing workflows, meeting value-based care metrics, and minimizing administrative burdens. With the ability to integrate seamlessly with major electronic health record (“EHR”) systems, Adageis’ platform supports providers in delivering more…

Continue Reading

FridayMar 14, 2025 2:28 pm

BioMedNewsBreaks — Calidi Biotherapeutics Inc.’s (NYSE American: CLDI) Novel Therapies Show Promise Against Aggressive Cancers

Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company that is pioneering proprietary technology designed to attack solid tumors, empowering the immune system to combat cancer. The company was featured in a recent article that discussed its platform, which utilizes antitumor virotherapies that selectively infect and kill cancer cells while stimulating the body’s immune response. Calidi’s pipeline includes three key therapies — RTNova, SuperNova and NeuroNova — that incorporate advanced technologies such as stem cells and antitumor viruses to target and destroy cancer cells. Calidi Biotherapeutics’ innovative therapies hold the potential to revolutionize cancer treatment by enhancing efficacy and stimulating…

Continue Reading

FridayMar 07, 2025 1:39 pm

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Collaborates to Support Potential Accelerated Pathway for ALS Treatment Candidate

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., is partnering with APST Research GmbH to analyze neurofilament light chain (“NfL”) data in evaluating its drug candidate, CNM-Au8®, for ALS treatment. Based in Germany, APST operates one of the largest ALS biomarker repositories, which includes data from over 4,300 ALS patients. This collaboration will enable Clene to compare NfL levels in patients treated with CNM-Au8 against historical ALS controls to assess the drug’s potential in slowing disease progression. The goal is to use these findings to support FDA accelerated approval for CNM-Au8 by demonstrating its ability to reduce NfL…

Continue Reading

WednesdayMar 05, 2025 3:30 pm

BioMedNewsBreaks — Adageis: Shaping the Future of Healthcare with AI-Powered Solutions

Adageis offers AI-driven solutions that help providers transition to and optimize value-based care models. “Healthcare is undergoing a major transformation as more organizations shift from fee-for-service to value-based care. Under value-based care models, providers are reimbursed based on patient outcomes rather than the volume of services rendered. This approach incentivizes proactive care, chronic disease management and overall cost efficiency,” a recent article explains. “Adageis, a forward-thinking healthcare technology company reshaping patient care through flexible AI-centric software solutions, is helping providers streamline their transition to value-based models. Through its ProActive Care Platform, Adageis enables healthcare organizations to optimize patient care while maximizing…

Continue Reading

WednesdayMar 05, 2025 2:42 pm

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Stands at the Forefront of Integrating New Oncology Therapies

Calidi Biotherapeutics (NYSE American: CLDI) is leveraging innovative platforms in a commitment to transform cancer treatment using advanced biotechnology. “The company is pioneering therapies that combine stem cells with antitumor viruses to create powerful cancer treatments. Antitumor viruses or virotherapies selectively infect and destroy cancer cells while sparing normal cells and, when paired with stem cells, their therapeutic potential is significantly amplified,” reads a recent article. “Calidi’s pipeline includes the proprietary SuperNova (‘SNV’) platform, which utilizes allogeneic adipose-derived mesenchymal stem cells (‘AD-MSCs’) as carriers for antitumor virotherapy. This approach has shown promise in preclinical studies and safety studies, with potential applications…

Continue Reading

ThursdayFeb 27, 2025 3:26 pm

BioMedNewsBreaks — Adageis Tackling Healthcare’s Value-Based Shift with AI-Driven Insights, Seamless Integration

Adageis, a forward-thinking healthcare technology company, is bringing AI-driven solutions that help providers harness data to improve care efficiency and financial performance amid an industry shift from fee-for-service models to value-based care. “A major hurdle in value-based care is identifying high-risk patients before they require costly interventions. Adageis addresses this with its Patented Risk Engine (‘PRE’), which analyzes clinical and demographic data to flag individuals most likely to develop chronic conditions or experience hospital readmissions. By surfacing these insights in real time, providers can intervene earlier, reducing avoidable emergency visits and improving long-term health outcomes,” reads a recent article. “Another…

Continue Reading

ThursdayFeb 20, 2025 1:29 pm

BioMedNewsBreaks — Adageis: Championing the Future of Healthcare with Powerful AI Tools

Adageis is positioned for opportunity as artificial intelligence reshapes healthcare. The technology company offers “flexible AI-centric software solutions for healthcare systems and providers in an easy-to-use application driving higher revenue… Its powerful and patented AI-centric ProActive Care Platform integrates seamlessly into existing workflows, making it an ideal partner for organizations navigating the shift toward value-based care,” reads a recent article. “Adageis’ proactive efficiency tools enable real-time monitoring, ensuring that patients receive timely interventions between visits. This approach reduces emergency department utilization and improves patient satisfaction… By prioritizing targeted solutions, Adageis not only transforms care delivery but also sets a benchmark for…

Continue Reading

FridayFeb 14, 2025 3:48 pm

BioMedNewsBreaks — Adageis Bringing AI Solutions to Identify High-Risk Patients, Address Care Gaps

Adageis is reshaping the healthcare landscape, offering solutions designed to streamline workflows and align incentives with quality care outcomes. “Central to this approach is the company’s ProActive Care Platform, a patented AI-powered system that provides actionable insights to healthcare providers. The platform equips Accountable Care Organizations (‘ACOs’), Clinically Integrated Networks (‘CINs’), and Independent Physician Associations (‘IPAs’) with the tools to deliver high-quality care while meeting the financial goals of value-based models,” reads a recent article. “At the heart of the platform lies the Patented Risk Engine (‘PRE’), an AI-driven tool that analyzes patient data to identify high-risk individuals and care gaps.…

Continue Reading

TuesdayFeb 11, 2025 1:30 pm

BioMedNewsBreaks — Adageis Seizing Opportunity in AI-Driven Healthcare Innovation

Adageis is positioned to capitalize as artificial intelligence (“AI”) plays a crucial role in meeting quality metrics, reducing costs and improving patient outcomes in the transition toward value-based healthcare. While the sector faces challenges — such as integrating AI tools into existing systems, ensuring data security and navigating regulatory frameworks — innovators like Adageis, a forward-thinking healthcare technology company, are stepping in to bridge the gap, offering scalable solutions that align with modern needs. “Adageis is at the forefront of AI-driven healthcare innovation. Its ProActive Care Platform provides providers, clinics and health systems with tools to enhance care delivery while addressing…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000